Group Cognitive Behavioral Therapy to Treat Depression in an Epilepsy Clinic Setting - Full Text View

Sponsors and Collaborators:	Stanford University Epilepsy Foundation
Information provided by:	Stanford University
ClinicalTrials.gov Identifier:	NCT00285740

Purpose

This study involves a form of group therapy called Cognitive Behavioral Therapy or CBT for depressed patients with Epilepsy. The CBT groups will be tailored for an epilepsy clinic population. There are 12 sessions of therapy in the study held once a week for 12 weeks.

Condition	Intervention
Epilepsy Depressive Disorder	Behavioral: Cognitive Behavioral Therapy (CBT) in a Group Format

Genetics Home Reference related topics: pyridoxal 5'-phosphate-dependent epilepsy

MedlinePlus related topics: Depression Epilepsy

U.S. FDA Resources

Study Type:	Interventional
Study Design:	Treatment, Randomized, Open Label, Active Control, Parallel Assignment, Efficacy Study

Further study details as provided by Stanford University:

Primary Outcome Measures:

Beck Depression Inventory

Secondary Outcome Measures:

NDDI

Estimated Enrollment:	60
Study Start Date:	August 2005
Estimated Study Completion Date:	January 2007

Detailed Description:

Depression is frequent in PWE and often missed for unclear reasons. Busy neurology clinics and their overworked physicians often lack psychiatric backup that may make inquiring about psychological issues problematic. In the psychiatric community, awareness of the need for depression intervention in the primary care clinic has been recognized for many years and several treatment models exist. This study will attempt to use one such model, i.e. Cognitive-Behavioral Therapy (CBT) using a group format and tailoring its use for an epilepsy clinic population.

Eligibility

Ages Eligible for Study:	18 Years to 65 Years
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria::- Patients will be screened with the Beck Depression Inventory. Those reaching the positive cut-off score of 11 (indicating at least a mild depression) will be entered into the study. Patients entered on antidepressants will be held at a stable dosage. Anti-epileptic drugs will also be maintained on the same dosage at entry into the study when possible clinically, after consultation with their neurologist. Exclusion Criteria:- Patients will be excluded if there is any active serious medical conditions, Standard Score<70 as assessed via the Wide Range Achievement Test, psychotic or substance abuse issues, those who are unable to maintain a stable dose of medications for the duration of study.

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00285740

Locations

United States, California
Stanford University School of Medicine
Stanford, California, United States, 94305

Sponsors and Collaborators

Stanford University

Epilepsy Foundation

Investigators

Principal Investigator:

John J Barry

Stanford University

More Information

Study ID Numbers:	2903, 34121
Study First Received:	January 31, 2006
Last Updated:	December 14, 2007
ClinicalTrials.gov Identifier:	NCT00285740
Health Authority:	United States: Institutional Review Board

Study placed in the following topic categories:

Depression
Mental Disorders
Epilepsy
Mood Disorders

Central Nervous System Diseases
Brain Diseases
Depressive Disorder
Behavioral Symptoms

Additional relevant MeSH terms:

Nervous System Diseases

ClinicalTrials.gov processed this record on January 16, 2009